Quiz Ref ID Antineutrophil cytoplasm antibody (ANCA)–associated vasculitis is characterized by a vasculitis that affects small- and medium-sized vessels and the presence of ANCA. ANCA-associated vasculitis includes microscopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis. The current standard therapies for remission induction of ANCA-associated vasculitis are the combination of high-dose glucocorticoids and either cyclophosphamide or rituximab.
1-3 Although those therapies have high remission rates of 80% to 90%, mortality at 5 years is still high at 10% to 20%. Infections and cardiovascular diseases due to treatment are the main causes of death in patients with ANCA-associated vasculitis, along with active vasculitis.
4,5 There are also adverse events of treatment that significantly decrease patients’ quality of life, such as osteoporosis, peptic ulcers, myopathy, and cataracts, most of which are associated with high-dose glucocorticoids.